Scarica l'app Stockscreener
3.40
3.34%
0.11
Dopo l'orario di chiusura:
3.45
0.05
+1.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune launches education drive linking alcohol and liver health - Traders Union
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
ALT (Altimmune) Property, Plant and Equipment : $0.31 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) FCF Margin % : -74,800.00% (As of Dec. 2025) - GuruFocus
ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
Insider Buying: John Gill Acquires Additional Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune director Gill buys $31k in company stock - Investing.com UK
Altimmune director Gill buys $31k in company stock By Investing.com - Investing.com Australia
Altimmune (ALT) director makes open-market share purchase - Stock Titan
Despite Recent Gains, Altimmune Insiders Are Still Down US$29k - 富途牛牛
Altimmune Inc.’s New Price Target Ignites Investor Interest - timothysykes.com
Altimmune Stock Outlook Brightens as Analysts Raise Price Targets - StocksToTrade
Altimmune’s Stock Target Raised as MASH Program Gains Momentum - timothysykes.com
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street - TipRanks
Altimmune’s Price Surge After H.C. Wainwright Strengthens Outlook - StocksToTrade
ALT stock has nearly halved in the past year, so why does Wall Street see almost 500% upside? - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmu - GuruFocus
Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase - Stock Titan
Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy - Stock Titan
Options Flow: Will Altimmune Inc announce a stock split2026 Market WrapUp & Real-Time Buy Signal Alerts - baoquankhu1.vn
Top 10 stocks under $5 that could triple - MSN
ALT (Altimmune) Common Stock : $0.01 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) Shares Outstanding (Diluted Average) : 105.82 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) 5-Year RORE % : -16.56% (As of Dec. 2025) - GuruFocus
Pullback Watch: Can Altimmune Inc disrupt its industrySell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Altimmune Inc. (ALT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALT (Altimmune) FCF Yield % : -17.19 (As of Mar. 27, 2026) - GuruFocus
ALT (Altimmune) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2025) - GuruFocus
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Jefferies reiterates Buy on Altimmune stock, keeps $28 target - Investing.com UK
Jefferies reiterates Buy on Altimmune stock, keeps $28 target By Investing.com - Investing.com India
Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares - Stock Titan
ALT (Altimmune) EPS without NRI : $-1.01 (TTM As of Dec. 2025) - GuruFocus
Altimmune appoints Luis Sanay as vice president of investor relations to strengthen financial communications - Traders Union
ALT Pemvidutide Uncovered: How It Stands Apart in MASH - Bitget
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026 - Bitget
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms - Yahoo Finance Singapore
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts - TradingView
ALT Pemvidutide Explained: What Makes It Different in MASH - Yahoo Finance
Altimmune a new buy at Truist on pemvidutide promise - MSN
HC Wainwright bullish on Altimmune (ALT) amid growing focus on treatments for metabolic and liver diseases - MSN
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - stocktitan.net
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):